BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 24359238)

  • 1. Future directions in the clinical management of amyloid light-chain amyloidosis.
    Haider S; Ahmad N; Anaissie E; Driscoll JJ
    Leuk Lymphoma; 2014 Oct; 55(10):2241-51. PubMed ID: 24359238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [AL amyloidosis].
    Jaccard A; Desport E; Mohty D; Bridoux F
    Rev Med Interne; 2015 Feb; 36(2):89-97. PubMed ID: 25194219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney and liver involvement in monoclonal light chain disorders.
    Pozzi C; Locatelli F
    Semin Nephrol; 2002 Jul; 22(4):319-30. PubMed ID: 12118397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New and developing therapies for AL amyloidosis.
    Zumbo G; Sadeghi-Alavijeh O; Hawkins PN; Fontana M
    Expert Opin Pharmacother; 2017 Feb; 18(2):139-149. PubMed ID: 28002971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy.
    Cohen AD; Comenzo RL
    Hematology Am Soc Hematol Educ Program; 2010; 2010():287-94. PubMed ID: 21239808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.
    Gertz MA
    Am J Hematol; 2011 Feb; 86(2):180-6. PubMed ID: 21264900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2016 Sep; 91(9):947-56. PubMed ID: 27527836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Light chain (AL) amyloidosis: update on diagnosis and management.
    Rosenzweig M; Landau H
    J Hematol Oncol; 2011 Nov; 4():47. PubMed ID: 22100031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
    Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
    Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How we treat systemic light-chain amyloidosis.
    Chaulagain CP; Comenzo RL
    Clin Adv Hematol Oncol; 2015 May; 13(5):315-24. PubMed ID: 26352777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
    Comenzo RL
    Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights and modern treatment of AL amyloidosis.
    Chaulagain CP; Comenzo RL
    Curr Hematol Malig Rep; 2013 Dec; 8(4):291-8. PubMed ID: 24026941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of novel therapies in the treatment of light chain amyloidosis.
    Varga C; Titus SE; Toskic D; Comenzo RL
    Blood Rev; 2019 Sep; 37():100581. PubMed ID: 31167719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.
    Muchtar E; Buadi FK; Dispenzieri A; Gertz MA
    Acta Haematol; 2016; 135(3):172-90. PubMed ID: 26771835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.